0.58

0.07% -0.0004

After Hours: .57 -0.01 -1.72%

Pasithea Therapeutics Corp (KTTA)

Overview News Price History Financials Discussions Forecast

Pasithea Therapeutics Corp stock is traded at $0.58, with a volume of 222.70K. It is down -0.07% in the last 24 hours and up +26.09% over the past month. Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.

Previous Close:

$0.5804

Open:

$0.5804

24h Volume:

222.70K

Relative Volume:

0.33

Market Cap:

$19.38M

Revenue:

Net Income/Loss:

$-19.73M

P/E Ratio:

-0.2796

EPS:

-2.0742

Net Cash Flow:

$-16.94M

1W Performance:

+3.57%

1M Performance:

+26.09%

6M Performance:

-29.27%

1Y Performance:

-27.14%

1-Day Range:

$0.57

$0.5926

1-Week Range:

$0.55

$0.595

52-Week Range:

$0.281

$2.06

Pasithea Therapeutics Corp Stock (KTTA) Company Profile

Name

Pasithea Therapeutics Corp

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(702) 514-4174

Address

1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

KTTA's Discussions on Twitter

Compare KTTA vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KTTA Pasithea Therapeutics Corp	0.58	15.70M	0	-19.73M	-16.94M	-2.0742
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Pasithea Therapeutics Corp Stock (KTTA) Latest News

Sep 03, 2026

Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences - globenewswire.com

Sep 03, 2026

Aug 28, 2026

Enterprise value to revenue forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView

Aug 28, 2026

Aug 21, 2026

Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance - TipRanks

Aug 21, 2026

Pasithea Therapeutics Received Notice of Noncompliance - TradingView

Aug 21, 2026

Pasithea (NASDAQ: KTTA) gets Nasdaq reprieve before possible delisting - Stock Titan

Aug 21, 2026

Aug 19, 2026

Pasithea (KTTA) Q1 2026 Earnings: EPS Clears the Reported Estimate; Session Move: The Stock Ends Down 1.21% in the Latest ReadingLow Growth Earnings - Vinanet

Aug 19, 2026

Aug 14, 2026

Pasithea Therapeutics Company Profile & Introduction - Moomoo

Aug 14, 2026

Pasithea Therapeutics Corp reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 14, 2026

Pasithea Therapeutics Corp. Q2 2026: Net loss $(5.27M), EPS $(0.16) — 10-Q Summary - TradingView

Aug 14, 2026

KTTA: Q2 2026 net loss rose to $5.27M as R&D spending surged; cash reserves at $45.7M - TradingView

Aug 14, 2026

Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock - Stock Titan

Aug 14, 2026

Aug 11, 2026

Enterprise value to EBIT forward of Pasithea Therapeutics Corp. – NASDAQ:KTTAW - TradingView

Aug 11, 2026

Aug 10, 2026

Pasithea Therapeutics Corp expected to post a loss of 16 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 08, 2026

Pasithea Therapeutics (KTTA) Jumps 14% as Price Approaches Key ResistanceMotive Wave - dars.gov.et

Aug 08, 2026

Aug 07, 2026

Pasithea Therapeutics Corp. SEC Filing (Aug 7, 2026) - Stock Titan

Aug 07, 2026

Aug 05, 2026

Pasithea Therapeutics Corp. Revenue Breakdown – BOATS:KTTAW - TradingView

Aug 05, 2026

Aug 01, 2026

Pasithea Therapeutics (KTTA) Edges Higher: Micro-Cap Biotech Approaches Key Resistance at $0.48TRIN Signal - vinanet.vn

Aug 01, 2026

Jul 31, 2026

Opaleye group (NASDAQ: KTTA) discloses 6.14% Pasithea Therapeutics ownership in 13G/A - stocktitan.net

Jul 31, 2026

Jul 29, 2026

Pasithea Therapeutics (NASDAQ: KTTA) sets virtual 2026 meeting and reverse split vote - Stock Titan

Jul 29, 2026

Jul 28, 2026